I reported previously (see here) on Israel’s Entera Bio and its treatment for hypoparathyroidism. Entera Bio has just signed a research and licensing agreement with US multinational Amgen to develop a new oral molecule-based treatment that currently is given via … Continue reading →

I reported previously (Apr 2014) on Israel’s Entera Bio which is testing treatments for disorders in the parathyroid gland, and osteoporosis. Entera Bio has now filed for floating the biotech on NASDAQ to fund Phase II/III trials of its treatment … Continue reading →

Israel’s Entera Bio has obtained orphan status from the US FDA for its oral treatment for hypoparathyroidism (decreased function of the parathyroid glands). The condition results in muscle cramping, twitching, or involuntary contraction, and several other symptoms. http://www.globes.co.il/en/article-dna-biomedical-jumps-on-orphan-drug-status-1000933656